CTRI/2019/03/018218尚未招募未知
A randomized, double-blind, parallel, single dose comparative pharmacokinetic study of AryoTrust (Trastuzumab) powder for concentrate for solution for intravenous infusion and â??HERCEPTINâ?? (Trastuzumab) powder for concentrate for solution for intravenous infusion in healthy, adult, male subjects.
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1) Age: 18 to 45 years, both inclusive
- •2) Gender: Male
- •3) BMI: 18.5 to 30.0 weight in kg/(height in meter)2 both inclusive; BMI value should be rounded off to one significant digit after decimal point (e.g. 30.04 rounds down to 30.0, while 18.45 rounds up to 18.5).
- •4) Volunteer having body weight at least 50 Kg.
- •5) Non-smokers and non-tobacco user (i.e. having no past history of smoking and tobacco consuming for at least one year prior to study)
- •6) Able to communicate effectively with study personnel.
- •7) Able to give written informed consent to participate in the study.
- •8) Willing and able to comply with the study procedures, restrictions and requirements as judged and confirmed by the principal or sub-investigator
- •9) Male subjects must agree that they and their female spouse/partners will use adequate contraception or be of non-childbearing potential.
- •10) All volunteers must be judged by the principal or sub-investigator or physician as normal and healthy during a pre-study safety assessment performed within 28 days of the first dose of study medication
排除标准
- •1) History of allergic responses/exposure to Trastuzumab or murine proteins or other related drugs, or antibodies.
- •2) Have significant diseases or clinically significant abnormal findings during screening [medical history, physical examination, vital signs, laboratory evaluations, pulmonary function test, ECG, Echocardiography (LVEF of < 60%) and chest X-ray recording].
- •3) Any disease or condition like diabetes, psychosis or others which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, ophthalmic, pulmonary, metabolic, endocrine, immunological, respiratory, central nervous system or any other body system.
- •4) History or presence of bronchial asthma.
- •5) Use of any hormone replacement therapy within 3 months prior to the study medication administration.
- •6) A depot injection or implant of any drug within 3 months prior to the study medication administration.
- •7) Use of enzyme-modifying drugs within 30 days prior to the study medication administration.
- •8) History or evidence of drug dependence or of alcoholism or of moderate alcohol use.
- •9) History of difficulty with donating blood or difficulty in accessibility of veins.
- •10) A positive hepatitis screen (includes subtypes B & C).
- •11) A positive test result for HIV antibody and / or syphilis (RPR/VDRL).
- •12) Volunteers who have received a known Investigational drug within 03 months of the administered drug prior to the study medication administration or have donated blood or loss of blood 50 ml to 100 ml within 30 days or 101 ml to 200 ml within 60 days or >200 ml within 90 days (excluding volume drawn at screening for this study) prior to first dose of study medication, whichever is greater.
- •13) Intolerance to venipuncture
- •14) Any food allergy, intolerance, restriction or special diet that, in the opinion of the Principal Investigator or Sub-Investigator, could contraindicate the volunteerâ??s participation in this study.
- •15) Institutionalized volunteers.
- •16) Volunteer with history of angina, dyspnea, orthopnoea, congestive heart failure or myocardial infarction.
- •17) History of any cancer, including carcinoma in situ.
- •18) Use of prescription or non-prescription drugs, including analgesics, herbal remedies, dietary supplements (including St. Johnâ??s Wort, but with the exception of paracetamol, NSAIDs, Corticosteroids and Antihistamines or vitamins) within 14 days prior to the study medication administration, unless in the opinion of the Investigator, the medication will not interfere with the study procedures or compromise subject safety
- •19) Use of haematopoetic growth factors, monoclonal antibodies or immunoglobulins within last 6 months prior to the study medication administration.
- •20) Major surgery or major trauma within past one year of screening or anticipated need for any surgery during the study duration.
- •21) Participation in a study with Trastuzumab or HER 2 targeted antibody or any prior exposure to these drugs or any other monoclonal antibody drugs.
- •22) Neutrophil count less than the lower limit of normal range during screening.
- •23) Volunteers who have received live vaccine(s) within 30 days prior to screening or who will require a vaccine(s) between Screening and the End of Study visit.
研究者
相似试验
尚未招募
1 期
Pharmacokinetic study of ZRC-3113 (Zydus Bevacizumab) and â??Avastinâ?¢â?? (Bevacizumab) in Healthy, Adult, Male subjectsCTRI/2020/01/022946Cadila Healthcare Ltd
已完成
不适用
A study comparing the blood levels of two trastuzumab formulations given as a single dose in healthy adult males.breast cancerACTRN12616000084482Dr Reddy's laboratories (Australia) Pty Ltd32
已完成
1 期
comparative pharmacokinetic study of Zydus Adalimumab (ZRC-3197) Injection and HUMIRA® Adalimumab Injection in healthy adult human subjects.CTRI/2019/01/017346Cadila Healthcare Ltd154
已完成
不适用
A two-part, single dose, randomized, single-blinded, placebo controlled, phase I study to assess the safety and pharmacokinetics of oral MT1980 in healthy volunteers when dosed in the fasted stateNL-OMON51342Monument Therapeutics Limited26
已完成
不适用
A single dose, randomised, double-blind parallel group study to compare the pharmacokinetics and pharmacodynamics of PB006 with Tysabri® in healthy subjectsNL-OMON49168Polpharma Biologics S.A.149